Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M250,129Revenue $M53,634Net Margin (%)39.1Z-Score4.3
Enterprise Value $M256,884EPS $4.1Operating Margin %20.9F-Score6
P/E(ttm))26.2Cash Flow Per Share $0Pre-tax Margin (%)22.9Higher ROA y-yY
Price/Book3.310-y EBITDA Growth Rate %1.3Quick Ratio1.2Cash flow > EarningsY
Price/Sales4.85-y EBITDA Growth Rate %-0.6Current Ratio1.4Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %14.2ROA % (ttm)16.4Higher Current Ratio y-yY
Dividend Yield %2.6Insider Buy (3m)0ROE % (ttm)29.1Less Shares Outstanding y-yY
Payout Ratio %63.0Shares Outstanding M2,399ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSRuane Cunniff 2014-12-31 Sold Out $85.02 - $96.65
($92.56)
$ 104.2811%Sold Out0
NVSHOTCHKIS & WILEY 2014-09-30 Reduce-0.21%$85.25 - $94.8
($90.27)
$ 104.2813%Reduce -98.51%9,646
NVSRuane Cunniff 2014-09-30 Buy $85.25 - $94.8
($90.27)
$ 104.2813%New holding7,772
NVSHOTCHKIS & WILEY 2014-06-30 Reduce-0.52%$82.51 - $90.98
($87.73)
$ 104.2816%Reduce -71.80%649,519
NVSDodge & Cox 2014-06-30 Add0.4%$82.51 - $90.98
($87.73)
$ 104.2816%Add 10.04%51,102,219
NVSChris Davis 2013-09-30 Sold Out -0.01%$70.66 - $77.08
($73.84)
$ 104.2829%Sold Out0
NVSVanguard Health Care Fund 2013-06-30 Sold Out -0.2%$68.42 - $75.5
($72.61)
$ 104.2830%Sold Out0
NVSVanguard Health Care Fund 2013-03-31 Reduce-0.71%$63.3 - $71.32
($67.87)
$ 104.2835%Reduce -85.39%726,200
NVSIrving Kahn 2013-03-31 Reduce-0.1%$63.3 - $71.32
($67.87)
$ 104.2835%Reduce -21.03%33,456
NVSVanguard Health Care Fund 2012-12-31 Reduce-0.99%$58.97 - $63.96
($61.82)
$ 104.2841%Reduce -70.59%1,461,400
NVSDodge & Cox 2012-12-31 Add0.11%$58.97 - $63.96
($61.79)
$ 104.2841%Add 2.65%48,438,459
NVSIrving Kahn 2012-12-31 Add0.04%$58.97 - $63.96
($61.82)
$ 104.2841%Add 10.43%42,368
NVSHOTCHKIS & WILEY 2012-12-31 Reduce-0.02%$58.97 - $63.96
($61.82)
$ 104.2841%Reduce -1.98%2,313,613
NVSKen Fisher 2012-12-31 Reduce-0.01%$58.97 - $63.96
($61.82)
$ 104.2841%Reduce -0.93%5,038,879
NVSTweedy Browne 2012-12-31 Reduce$58.97 - $63.96
($61.82)
$ 104.2841%Reduce -0.09%301,399
NVSChris Davis 2012-12-31 Reduce$58.97 - $63.96
($61.82)
$ 104.2841%Reduce -0.09%33,100
NVSKen Fisher 2012-09-30 Buy 0.86%$55.24 - $61.51
($58.49)
$ 104.2844%New holding5,086,362
NVSDodge & Cox 2012-09-30 Add0.12%$55.24 - $61.51
($58.49)
$ 104.2844%Add 3.23%47,187,759
NVSMichael Price 2012-03-31 Sold Out -1.3%$53.31 - $58.33
($52.37)
$ 104.2850%Sold Out0
NVSKen Fisher 2012-03-31 Sold Out -0.13%$53.31 - $58.33
($52.37)
$ 104.2850%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15603.33view

Press Releases about NVS :

    Quarterly/Annual Reports about NVS:

      News about NVS:

      Articles On GuruFocus.com
      Amgen Reports An Upbeat Q1 Earnings Apr 23 2015 
      Top Weighted Stocks in Tweedy Browne Global Value Fund's Portfolio Apr 22 2015 
      Amgen’s Q1 Earnings Paints An Overall Positive Image To Investors Apr 22 2015 
      In Europe Really Recovering? Apr 19 2015 
      Amgen’s First Drug For Cardiovascular Disease Gets The Green Light Apr 17 2015 
      Bristol-Myers Signs An Exclusive Pact In Gene Therapy For Treating Cardiovascular Disorders Apr 08 2015 
      Biotech Momentum Indicators: Achaogen (AKAO), Novartis (NVS), VIVUS (VVUS) Apr 01 2015 
      Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
      Anacor Pharmaceuticals’ Q4 Was A Solid One For Investors Mar 16 2015 
      AbbVie Strikes The Biggest Deal For Treatment Of Cancer Mar 10 2015 


      More From Other Websites
      AbbVie Beats Q1 Estimates; Novartis, Alexion Mixed Apr 23 2015
      Drug Companies Pin Hopes On TrialReach To Enroll Patients In Clinical Trials Faster Apr 23 2015
      Early movers: PBR, MMM, CAT & more Apr 23 2015
      Europe shares fall on soft PMIs, Michelin gains Apr 23 2015
      Novartis keeps full-year target as Q1 earnings fall Apr 23 2015
      LLY CFO: Here's what's driving profits Apr 23 2015
      European Stocks Drop After Manufacturing, Services Miss Estimates Apr 23 2015
      Novartis Reports First-Quarter Profit That Beats Estimates Apr 23 2015
      Novartis starts to reap rewards of revamp Apr 23 2015
      Novartis posts Q1 profit beat despite dollar drag Apr 23 2015
      Novartis posts Q1 profit beat despite dollar drag Apr 23 2015
      Novartis (NVS) Beats on Earnings & Revenues - Tale of the Tape Apr 23 2015
      Divestment gains boost net earnings at drug company Novartis Apr 23 2015
      Divestment gains boost net earnings at drug company Novartis Apr 23 2015
      2:28 am Novartis AG beats by $0.14, misses on revs; reaffirms FY results Apr 23 2015
      Deutsche Bank Said to Pay EU2B to End Libor Probes Apr 23 2015
      Novartis warns of currency drag on 2015 earnings Apr 23 2015
      Novartis 1Q Sales $11.9B; Est. $12.8B Apr 23 2015
      Unipetrol Increases First-Quarter Net on Higher Refinery Margins Apr 23 2015
      Novartis Profit Boosted Disposals Apr 23 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK